RIDASCREEN® VDZ Monitoring

Intended use:

For in vitro diagnostic use. The RIDASCREEN^® VDZ Monitoring is an enzyme linked immunosorbent assay intended for the quantitative determination of vedolizumab (VDZ, Entyvio^®, anti- integrin α₄β₇) in human serum and plasma.

Product information

Vedolizumab (VDZ, Entyvio®) is approved for the treatment of patients with moderate to severe Crohn’s disease and ulcerative colitis in whom conventional therapy or anti-TNFα therapies were ineffective or not tolerated. It is a gut-specific, humanized monoclonal antibody targeting the α₄β₇-integrin protein, which is involved in the migration of lymphocytes to the gut. Similar as to anti-TNFα drugs, measurement of vedolizumab drug concentrations supports a personalized dosing strategy in patients treated with vedolizumab.

The RIDASCREEN® VDZ Monitoring and our other TDM assays are vital to personalize treatment of patients with Crohn’s disease and ulcerative colitis and better achieve therapeutic targets.

Key features:

• CE-marked versions of the ELISA tests of KU Leuven
• Highly specific antibodies
• Ready to use reagents
• Validated for use on automated ELISA systems, e.g. the Dynex DSX®